Welcome to our dedicated page for Creative Med Technology Hldgs SEC filings (Ticker: CELZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) provides direct access to the company’s official regulatory disclosures as a clinical-stage biotechnology issuer. These documents offer detailed insight into Creative Medical’s governance, financing activities, and progress across its regenerative medicine, regenerative immunotherapy, and AI-enabled biodefense platforms.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for information on CELZ’s business description, risk factors, research and development focus, and financial statements. These filings typically discuss the company’s key programs, including AlloStem/CELZ-201 (olastrocel), ImmCelz, and iPScelz, as well as clinical initiatives in degenerative disc disease, chronic lower back pain, Type 1 diabetes, and biodefense-related indications.
Current reports on Form 8-K highlight material events such as warrant exercise inducement agreements, unregistered sales of equity securities, and compensation decisions for senior executives. For example, recent 8-K filings describe inducement warrant transactions used to raise working capital and general corporate funds, along with related advisory arrangements.
Proxy statements on Schedule 14A (DEF 14A) detail matters submitted to stockholders, including the election of directors, advisory votes on executive compensation, auditor ratification, and special meeting proposals to approve the exercise of inducement warrants in accordance with Nasdaq Listing Rule 5635(d). These documents provide visibility into CELZ’s corporate governance structure and stockholder voting items.
Through this page, users can also monitor registration statements and any available Form 4 insider transaction reports, where applicable, to understand how securities are being issued and how insiders transact in the company’s stock. Stock Titan enhances this information with AI-powered summaries that explain the key points of lengthy filings, highlight important changes, and help readers interpret complex disclosures in 10-Ks, 10-Qs, 8-Ks, and proxy materials.
Together, these SEC filings form an authoritative record of Creative Medical Technology Holdings’ regulatory, financial, and corporate activities, supporting deeper analysis of CELZ as a clinical-stage biotechnology company.
Creative Medical Technology Holdings reported a net loss of $1.4 million for the quarter ended March 31, 2026, slightly improved from $1.6 million a year earlier, as it reduced research and development spending.
Revenue was negligible, with no sales this quarter versus $3,000 in the prior-year period. Cash and cash equivalents totaled $5.7 million, down from $7.2 million at year-end, after using $1.3 million in operating cash and $175,000 for investments, including a related-party SPAC initiative and convertible notes.
The company continues to focus on its regenerative medicine pipeline, highlighting progress in AlloStemSpine® chronic lower back pain trials, CELZ-201 programs for Type 1 diabetes, and collaborations using induced pluripotent stem cells and artificial intelligence.
Creative Medical Technology Holdings, Inc. files an amended annual report outlining its 2025 governance, executive pay, related-party transactions and auditor fees. The company reports a non‑affiliate market value of common stock of $4,633,334 as of June 30, 2025 and 3,696,668 shares outstanding as of March 20, 2026.
The CEO earned total 2025 compensation of $732,720 and the CFO $560,000, with employment agreements providing salary, target bonuses and equity grants plus two years of salary and bonuses upon certain terminations. Three of five directors are independent and all three independents serve on the audit committee.
The filing details related-party arrangements, including a prior $5,000,000 purchase of research tools from an affiliate, a patent purchase agreement with contingent cash-or-stock milestone payments and royalties, the Bionance investment initiative with up to $600,000 of member commitments, and a $125,000 investment in a SPAC sponsor alongside the CEO. Audit and audit-related fees to Haynie & Company totaled $90,500 for 2025.
Creative Medical Technology Holdings filed its annual report detailing 2025 operations, clinical progress and risks. The company is a commercial-stage biotech focused on regenerative therapies for Type 1 and Type 2 diabetes, chronic lower back pain, infertility and other immune‑mediated conditions.
Key 2025 milestones include continued Phase I/II trials for Type 1 diabetes (CELZ-201 CREATE-1) and AlloStemSpine® (CELZ-201 ADAPT), Fast Track designation for CELZ-201-DDT, orphan drug designation for brittle Type 1 diabetes, and expansion of its iPSC and AI collaborations with Greenstone Biosciences.
Financially, the company reported an operating loss of about $6.1 million in 2025, research and development expense of about $2.3 million, minimal product revenue of $6,000, and cash and short‑term U.S. treasuries of about $7.2 million as of December 31, 2025. Management discloses a need for additional capital to fund ongoing trials and platform development.
Creative Medical Technology Holdings, Inc. is registering up to 2,790,340 shares of common stock for resale by existing investors, all issuable upon exercise of Inducement Warrants from an October 29, 2025 warrant exercise transaction. These are secondary sales by the selling stockholders, so the company will not receive any proceeds from the resale of the shares, although it has already received cash from the prior exercise of existing warrants and may receive additional funds if the new warrants are exercised for cash.
The Inducement Warrants currently have a $2.86 exercise price, were issued as part of an inducement for holders to exercise earlier warrants at $3.75 per share, and become exercisable for five years only after stockholder approval of the underlying share issuance. If all warrants are exercised, common stock outstanding would increase from 3,494,668 to 6,285,008 shares. Large holders such as Armistice Capital and Hudson Bay are subject to 4.99% or 9.99% beneficial ownership limits, and the company warns that significant resales could pressure the share price.
Creative Medical Technology Holdings, Inc. is registering 2,790,340 shares of common stock for resale by existing investors, issuable upon exercise of inducement warrants issued in an October 29, 2025 warrant exercise transaction. These are secondary sales, so the company will not sell any shares in this offering and will not receive proceeds from any resale, though it will receive cash if the warrants are exercised and plans to use those funds for working capital and general corporate purposes. The prospectus allows selling stockholders to dispose of shares in various ways over time, which could put pressure on the stock price if large blocks are sold. After full warrant exercise, common shares outstanding would be 6,045,440, based on 3,255,100 shares outstanding before the offering.
Creative Medical Technology Holdings (CELZ) called a special meeting to approve, for purposes of Nasdaq Listing Rule 5635(d), the exercise in full of inducement warrants covering 2,790,340 shares of common stock at an exercise price of $2.86 per share. The warrants, issued on October 29, 2025 in a private placement, are not exercisable until stockholders approve this proposal and would then be exercisable for five years following approval.
The board unanimously recommends a vote FOR. The company notes that approval could lead to dilution for existing stockholders and that subsequent sales of shares issued upon exercise could pressure the stock price. If the proposal is not approved, the company must hold additional stockholder meetings every 90 days until approval is obtained.
Creative Medical Technology Holdings (CELZ) reported a compensation action. On November 6, 2025, the Board’s Compensation Committee approved bonuses of $100,000 for CEO Timothy Warbington and $25,000 for CFO Donald Dickerson.
The company also noted its common stock trades on Nasdaq under CELZ. An Exhibit 104 cover page interactive data file was included.
Creative Medical Technology Holdings (CELZ) filed its Q3 2025 10‑Q, showing continued operating investment and recent warrant-driven funding. Cash was $5.38 million at September 30, 2025, with positive working capital of about $5.15 million. Q3 net loss was $1.24 million (vs. $1.04 million a year ago), and the nine‑month net loss was $4.11 million. Revenue remained minimal at $3,000 year-to-date.
Operating expenses reflected higher selling, general and administrative costs, partly offset by lower R&D as the AlloStemSpine ADAPT trial moved through recruitment. The company raised approximately $3.7 million in March 2025 via warrant exercise inducements; a subsequent October 25, 2025 inducement generated about $3.8 million in net proceeds, with those new warrants’ exercise price reset to $2.86 on November 4, 2025 based on VWAP mechanics. Warrants outstanding were 4,147,478 at quarter-end.
As of November 1, 2025, CELZ had 2,580,532 common shares outstanding. Management highlighted progress across clinical programs and maintained effective disclosure controls.
Creative Medical Technology Holdings (CELZ) called a special meeting to seek stockholder approval, as required by Nasdaq Listing Rule 5635(d), to permit the full exercise of warrants covering 2,790,340 shares of Common Stock issued on October 29, 2025.
The Inducement Warrants have an exercise price of $3.75 per share, subject to reduction to the lowest VWAP during the five trading days starting on their issuance date. They are not exercisable until stockholders approve the proposal and will then be exercisable for five years following approval. The company agreed to file a registration statement to register the resale of the underlying shares.
The filing notes potential dilution to existing holders if the warrants are exercised and that sales of the resulting shares could pressure the stock price. If approval is not obtained, the company must call additional stockholder meetings every 90 days until approval is secured, which it states would add cost. The Board unanimously recommends a vote FOR the proposal.
Creative Medical Technology Holdings (CELZ) entered warrant exercise inducement agreements. Holders agreed to exercise Existing Warrants for 1,116,136 shares at $3.75 per share, generating approximately $4.2 million in gross proceeds. Net proceeds will be used for working capital and general corporate purposes.
In exchange, CELZ issued Inducement Warrants to purchase 2,790,340 shares with a $3.75 exercise price, subject to reduction to the lowest VWAP during the five trading days starting on the issuance date. These Inducement Warrants are not exercisable until stockholder approval is obtained under Nasdaq rules and will then be exercisable for five years from that approval date.
The company also reduced the exercise price of certain 2022 and 2021 warrants to $4.73 per share and issued additional warrants for up to 279,036 shares to a consenting investor. Existing Warrant shares are registered under an effective Form S-3; the Inducement Warrants were issued privately, and CELZ agreed to file a Form S-3 within thirty days to register the resale of shares issuable upon their exercise. Roth Capital Partners will receive an 8% advisory fee on gross proceeds and $40,000 for legal expenses.